Scientific deep-dive

Wegovy Pill vs Injection: Is the Pill as Good as the Shot?

The Wegovy pill cut weight 13.6% in its trial and the shot 14.9% in its own, and an indirect comparison could not tell them apart. What differs: the daily fasting rule, the dose steps, side effects, the 7.2 mg pen and about $50 a month.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
10 min read·6 citations

Part of The next obesity drugs, and what their trials showed

On the evidence available, the Wegovy pill is about as effective as the Wegovy shot: the 25 mg daily tablet cut body weight by 13.6% at 64 weeks in its trial, and the 2.4 mg weekly injection by 14.9% at 68 weeks in its own.[2] No trial has put the two against each other. An indirect comparison of those two trials found them comparable across every outcome examined, with a small, uncertain edge to the injection.[1] That conclusion is reasonable but narrower than it sounds. The practical differences are the daily fasting routine, the dose steps, and about $50 a month in price.

About this article. Written from the current FDA label for Wegovy, which covers the injection and the tablets in one document (revised June 2026), the two published trials behind each form, a published indirect comparison of them, and Novo Nordisk’s own self-pay prices. Nothing here is a reason to start, stop or switch a drug. Switching between forms follows a specific schedule in the label, set by the prescriber.

Wegovy pill vs injection: the trial results

Each form was approved on its own placebo-controlled trial. The tablet’s is OASIS 4, listed in the label as Study 7: 307 adults without diabetes whose BMI put them in the obesity range, or in the overweight range with a related health problem, randomized two to one to 25 mg or placebo.[2][3] The injection’s main weight trial is STEP 1, Study 2 in the label, with 1,961 adults of the same description.[4]

Headline results as printed in the Wegovy FDA label (Tables 8 and 11). Each column comes from a different trial; the drug-versus-placebo difference is the fairer figure to set side by side.
MeasurePill 25 mg daily (OASIS 4)Injection 2.4 mg weekly (STEP 1)
People on drug / placebo205 / 1021,306 / 655
Length64 weeks68 weeks
Weight change on drug−13.6%−14.9%
Weight change on placebo−2.4%−2.4%
Difference from placebo−11.2 points−12.4 points
Lost 15% or more47% vs 5.5%47.9% vs 4.8%
Lost 20% or more27.9% vs 3.1%30.2% vs 1.7%

Row by row, the numbers line up closely, but they come with caveats. The pill trial ran four weeks shorter and was about a sixth the size, so its estimates carry wider uncertainty. Both report the treatment-regimen result, which counts everyone randomized, including people who stopped taking the drug.[4][2] The OASIS 4 paper itself reports a placebo result of −2.2% rather than the label’s −2.4%, a small reminder that model choices move these figures a little.[3]

Why similar results are expected

These are the same molecule. The obstacle with oral delivery is that peptides are destroyed in the stomach, which is why the oral formulation requires an absorption enhancer, an empty stomach, minimal water, and a thirty-minute wait.

The indirect comparison’s stated rationale is that the two formulations achieve comparable systemic exposure, meaning similar drug levels in the blood. If that holds, a similar effect is what you would expect, and the analysis confirms a prediction.

The label puts numbers on that, with one catch. Blood levels on the 25 mg tablet are predicted to match the 2.4 mg pen on average, but they spread far wider: in 90% of people, average concentrations fell between 27 and 186 nmol/L on the tablet, against 51 to 110 nmol/L on the injection.[2] Only about 1% to 2% of each tablet’s dose is absorbed at all.[2] On average the exposure is the same, but any one person’s is less predictable on the pill.

Percentage weight change, oral 25 mg against injectable 2.4 mg, indirect comparison of OASIS 4 and STEP 1.[1]
AnalysisDifference favoring the injection95% CI
Treatment-regimen estimand1.01 percentage points−1.61 to 3.63
Efficacy estimand0.55 percentage points−2.25 to 3.35

Safety profiles were described as broadly comparable, and small numerical advantages appeared for each formulation on different endpoints. The analysis was commissioned by Novo Nordisk, which sells both forms, and several of its authors work for or advise the company.[1]

What 'comparable' is claiming

Look at the interval: −1.61 to 3.63. The data are compatible with the oral formulation being 1.6 percentage points better, and equally compatible with the injection being 3.6 points better. “Comparable” here means the analysis could not distinguish them, which falls short of showing they are the same.

Demonstrating equivalence requires deciding in advance how large a difference would matter, and then showing the interval sits entirely inside it. That boundary is called a non-inferiority margin, and the researchers choose it.

This analysis uses the FDA’s 5% threshold for clinical relevance in weight management, and the intervals do sit comfortably inside it. That is a legitimate anchor, and a wide one: a five percentage point margin is roughly a third of what semaglutide achieves in total. The wider the margin, the easier equivalence is to claim.

A five percentage point margin is roughly a third of what semaglutide achieves in total.

On the evidence available, then, there is no demonstrated meaningful difference between the two formulations at these doses, judged against a threshold regulators consider reasonable. That is useful to know, and it is weaker than “they are the same.”

Where the shot pulls ahead: Wegovy 7.2 mg

The comparison above stops at 2.4 mg, but the injection now goes higher. The label allows the weekly dose to rise to 7.2 mg (sold as Wegovy HD) once 2.4 mg has gone smoothly for four weeks or more and further loss is clinically warranted.[2] In STEP UP, 7.2 mg reduced weight by 18.7% at 72 weeks against 15.6% on 2.4 mg, a difference of 3.1 points.[5] The tablet has no step above 25 mg.[2]

The extra loss has a price in tolerability. Dysesthesia, an altered or burning skin sensation, was reported by 22.9% on 7.2 mg against 6.0% on 2.4 mg in that trial.[5] What the high-dose pen costs is in what Wegovy 7.2 mg costs.

Dose steps: pill vs pen

Both forms start low and climb, to limit stomach side effects. The pill moves every 30 days through four strengths. The pen moves every four weeks through five.[2]

Starting and escalation schedules from the Wegovy FDA label, Tables 1 and 2.
StepWegovy pill (once daily)Wegovy injection (once weekly)
Start1.5 mg, days 1 to 300.25 mg, weeks 1 to 4
Step 24 mg, days 31 to 600.5 mg, weeks 5 to 8
Step 39 mg, days 61 to 901 mg, weeks 9 to 12
Step 425 mg from day 91 (maintenance)1.7 mg, weeks 13 to 16
Maintenance25 mg2.4 mg (or 1.7 mg); up to 7.2 mg if needed

The pill reaches its full dose about four weeks sooner. If 25 mg proves too hard to tolerate, the label’s fallback is not a lower tablet but a switch to the 1.7 mg pen.[2] Moving between forms is also scheduled: after a final 2.4 mg injection, the first 25 mg tablet comes seven days later; after a final 25 mg tablet, the 2.4 mg pen begins the next day.[2]

The daily routine the pill requires

The pen goes in once a week, on the same day, at any hour, with or without food.[2] The tablet comes with rules that hold every morning:

  • First thing in the morning, before eating, with a sip of plain water: 4 ounces is the limit.[2]
  • Swallowed whole; never split, crushed or chewed.[2]
  • Then at least 30 minutes with no food, no other drinks and no other oral medicines.[2]

The rules change how much drug gets in. In the label’s absorption studies, more semaglutide reached the blood with less water and with a longer wait before eating.[2] A rushed morning means a smaller dose. For people with several morning medicines, or a thyroid drug that has its own empty-stomach rule, that half hour is the practical obstacle. The pill’s storage, missed-dose rule and thyroid interaction are covered in Wegovy pill side effects.

Side effects: pill vs injection

The label says the tablet’s common side effects were similar in type and frequency to the injection’s.[2] Stomach and gut complaints dominate both: 74.0% on the 25 mg pill against 42.2% on placebo in OASIS 4, and 73% against 47% on the 2.4 mg pen.[3][2]

A few tablet-specific figures beside the injection's, all from the Wegovy FDA label. Different trials, so small gaps are not a verdict.
MeasurePill 25 mg vs placeboInjection 2.4 mg vs placebo
Stopped for a side effect6.9% vs 5.9%6.8% vs 3.2%
Gallstones2.5% vs 1%1.6% vs 0.7%
Dysesthesia5% vs 0%2% vs 1%

Neither form is clearly gentler. The pill showed somewhat more skin-sensation complaints and gallstones in its trial; the pen’s trials showed a larger gap over placebo in people quitting. The full symptom table and what dysesthesia feels like are on Wegovy pill side effects.

Cost per month: pill vs pen

Novo Nordisk self-pay prices through NovoCare, read October 2026. A pill month is a bottle of 30 tablets; a pen month is a box of 4 weekly pens (28 days).
Form and dosePer monthPer dayAbout per year
Pill, 25 mg$299$9.97$3,640
Injection, 2.4 mg$349$12.46$4,550
Injection, 7.2 mg (Wegovy HD)$399$14.25$5,200

At maintenance the pill is $50 a month cheaper than the 2.4 mg pen, and the gap widens a little because a pen box lasts 28 days rather than 30.[6] Early on it narrows: the pill’s first bottles are $149 and $199, while the pen’s two starter months cost $199 apiece for new patients, an offer that runs through December 31, 2026.[6] Novo Nordisk says pricing will be updated after that date.[6] Insurance, Medicare and telehealth seller prices are in what the Wegovy pill costs.

If you want to keep both forms open, some telehealth sellers list the pill and the pen side by side. Knownwell, an obesity-medicine practice that bills insurance first, prescribes the Wegovy pill, the Wegovy pen, Zepbound and Foundayo. Heally and ZipHealth list the Wegovy pill beside Wegovy injections and Zepbound; ZipHealth says its prices rise with the dose, and Heally says higher doses may cost more. Rex MD goes the other way, with one monthly price for the pill across every titration dose.

Others pair a pill with compounded injections. Healthicare lists the Wegovy pill at its first two doses next to compounded semaglutide and tirzepatide, and Good Life Meds sells the pill, with a separate membership fee, beside compounded semaglutide. Found and CLYR Health list Foundayo, a different GLP-1 pill, alongside their compounded plans, and Found bills brand drugs separately from its membership.

Good Girl Rx lists the brand Wegovy pill as well as compounded semaglutide and tirzepatide sold as injections, microdose injections and dissolving tablets. A compounded tablet is not the Wegovy pill, so check which of the two a plan names. SkinnyRx sells both: compounded semaglutide tablets at $149 for the first month, and the Wegovy pill through its membership from $248 a month. If it is the approved pill you want, our Wegovy pill board lists only sellers that name it in their price list.

Two things not to confuse

Who tends to fit which form

The differences that remain are practical. The tablet demands a daily routine of fasting, minimal water and no food for half an hour, which the weekly injection does not, and adherence to that routine is what determines whether the drug is absorbed at all. Which formulation suits someone depends more on that than on a one percentage point difference nobody could measure reliably.

  • The pill fits someone who dislikes needles, keeps a fixed morning routine, and pays cash, since it is the cheaper form at maintenance.[6] It also needs no refrigeration.
  • The pen fits someone with a crowded or irregular morning, several morning medicines, or a need for more weight loss than 2.4 mg delivers, since only the injection goes to 7.2 mg.[2]
  • Only the pen is approved under 18. The injection is labeled for children 12 and older with obesity; the tablets are labeled for adults only.[2]

Either way it is the same drug with the same boxed warning, and the choice belongs to the patient and prescriber. The drug’s other pages are on the Wegovy hub.

Frequently Asked Questions

As far as the evidence can tell, yes. The 25 mg pill cut weight by 13.6% at 64 weeks in its trial and the 2.4 mg shot by 14.9% at 68 weeks in its own. An indirect comparison found them comparable, with a small, uncertain edge of about one point to the injection. No trial has compared them directly.
It means the analysis could not distinguish them. The confidence interval runs from the oral being 1.6 points better to the injection being 3.6 points better, judged against the FDA's 5% threshold for clinical relevance, which is a wide margin.
At 2.4 mg, not measurably. But the injection can go up to 7.2 mg weekly, which produced 18.7% weight loss against 15.6% on 2.4 mg in the STEP UP trial. The pill stops at 25 mg.
At maintenance, yes. Novo Nordisk's self-pay price is $299 a month for the 25 mg pill and $349 for the 2.4 mg pen, and a pen box covers 28 days against 30 for a pill bottle.
The label allows it. Tablets at 25 mg begin seven days after a final 2.4 mg injection. In the other direction, the 2.4 mg pen begins on the day following a final 25 mg tablet. The switch is made by the prescriber.
No. This concerns oral semaglutide at 25 mg. The 7 and 14 mg strengths are the diabetes doses, and conclusions about one do not transfer to the other.

References

  1. 1.Plotkin M, Ivkovic M, Smith I, et al. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes Diabetes, Obesity and Metabolism. 2026. PMID: 42225300.
  2. 2.Novo Nordisk Inc. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets: US Prescribing Information (revised June 2026), Sections 1, 2, 5, 6.1, 12.3 and 14.2 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. 3.Wharton S, Lingvay I, Bogdanski P, et al.; OASIS 4 Study Group Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity N Engl J Med. 2025. PMID: 40934115.
  4. 4.Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2021. PMID: 33567185.
  5. 5.Wharton S, Freitas P, Hjelmesæth J, et al.; STEP UP trial group Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial Lancet Diabetes Endocrinol. 2025. PMID: 40961952.
  6. 6.Novo Nordisk Inc. NovoCare: Wegovy savings offer and self-pay pricing (pill and pen) NovoCare. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html

Rybelsus for Weight Loss: How Much Weight People Lose, and Why It's Less

Rybelsus is approved for type 2 diabetes, not weight. In its trials the 14 mg dose took off 3.1 to 4.4 kg in 26 weeks. Why the Wegovy pill does far more, what is known in people without diabetes, and why insurers won't cover it for weight.

10 min read

Comparing Trials That Never Met

We refused a cross-trial comparison in an earlier article. This article runs the methodologically proper version of it, and explains why it appears to contradict a head-to-head trial without actually doing so.

7 min read

An Oral Pill in a Diabetes Population

Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.

7 min read

The Dose That Stopped Helping

ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.

6 min read

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

7 min read

The Statistic That Asks If Groups Differ

A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.

7 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.1

Direct Meds

8.2

bmiMD

Starting below a standard dose, with microdose tiers

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →